Short answer
HERON THERAPEUTICS, INC. /DE/ (HRTX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $35M (down 7.8% year over year) with net income of −$5M.
Q3 2026 key financials · XBRL
- Revenue
- $35M
- −7.8% YoY · −6.4% QoQ
- Net income
- −$5M
- +71.4% YoY · +8.8% QoQ
- Operating margin
- -4.7%
- Gross margin
- 74.6%
- EPS (diluted)
- −$0.03
- +72.7% YoY · +0.0% QoQ
Source: XBRL data from the HERON THERAPEUTICS, INC. /DE/ (HRTX) Q3 2026 10-Q on SEC EDGAR. USD.
HERON THERAPEUTICS, INC. /DE/ Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $35.3M, down $3.0M YoY, with acute care $15.1M vs $12.3M and oncology $20.1M vs $25.9M
- Gross margin 74.6% vs 68.8% YoY, operating margin (4.7%) vs (10.7%)
- Best segment acute care sales up 22.5% to $15.1M, worst oncology sales down 22.2% to $20.1M
- Cash, cash equivalents and short-term investments $23.4M; operating cash use $4.5M versus $18.4M
- Proposed Asset Sale expected first quarter 2027, with $145.0M cash and 14,583,333 CorMedix shares; covenant default risk remains without closing or funding
Risk Factors
- Newly added asset-sale risk: CorMedix transaction announced November 8, 2026, requiring stockholder approval and other closing conditions
- Most material update, liquidity: $23.4 million cash and possible covenant noncompliance could trigger debt acceleration and going-concern doubt
- Regulatory risk: Post-sale assets may trigger Investment Company Act regulation, restricting investments, operations, and equity compensation
- Legal risk: June 1, 2026 Azurity judgment invalidated two patents and found ten others not infringed, with appeal briefing completed November 4, 2026
- Market risk: Nasdaq bid price below $1.00 triggered deficiency notice, with compliance required by December 22, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other HERON THERAPEUTICS, INC. /DE/ quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.